Navigation Links
Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, a Novel s-EH Inhibitor to Treat Type 2 Diabetes
Date:2/10/2009

HAYWARD, Calif., Feb. 10 /PRNewswire/ -- Arete Therapeutics Inc. today announced the initiation of a Phase IIa clinical trial for AR9281, an orally- administered soluble epoxide hydrolase (s-EH) inhibitor being developed for the treatment of type 2 diabetes. S-EH is an enzyme involved in the metabolism of arachidonic acid, a key signaling molecule implicated in diabetes, hypertension and inflammatory disorders.

"Our AR9281 Phase II clinical trial program breaks new ground in two key areas. This is the first clinical study of a s-EH inhibitor in patients, and the first study designed to establish proof of concept that s-EH inhibition modulates glucose metabolism or blood pressure in patients with impaired glucose tolerance and hypertension," said James Sabry, M.D., Ph.D., President and Chief Executive Officer of Arete Therapeutics. "AR9281 has demonstrated an excellent safety profile and activity in multiple animal models of type 2 diabetes, and has the advantage of inhibiting a novel drug target that differentiates it from currently marketed diabetes medications. With this promising drug profile, AR9281 has the potential to provide safe and effective therapy for patients with type 2 diabetes either as monotherapy or in combination with existing treatment regimens."

The Phase IIa multicenter, double-blind, placebo-controlled study will enroll 150 pre-diabetic patients with impaired glucose tolerance, mild obesity and mild to moderate hypertension. All patients enrolled in the study will be treatment-naïve for type 2 diabetes medications. The trial will evaluate two schedules of AR9281 and placebo using a parallel design to determine the feasibility of twice-a-day dosing. Each patient will receive 28 days of treatment. Endpoints for the trial include safety, tolerability, reduction of blood pressure and various measures of glucose and lipid metabolism, with results expected in the first quarter of 2010.'/>"/>

SOURCE Arete Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. CareTech Solutions Executive to Conduct Presentation on Creating a Healthy Revenue Cycle at AHIMA Convention and Exhibit
2. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
3. Arete Therapeutics Appoints Donald Santel to Board of Directors
4. CareTech Solutions Service Desk Equals Help Desk Plus
5. Nationally Recognized Diabetes Specialist Dr. Steven Edelman to Provide Educational Articles on Diabetes to MyCareTeam's Website Community
6. CareTech Solutions Named Best in KLAS for Extensive IT Outsourcing Services
7. EnovateIT Partners with CareTech Solutions to Create a Custom Product for Crittenton Hospital Medical Center, One of the Nation's Most Wired Hospitals
8. Prime Therapeutics Receives TIPPS Certification
9. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
10. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
11. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Washington, DC (PRWEB) August 01, 2014 ... approach offer health plans and employers effective options ... of narrow networks argue that they can enhance ... and administrative fees. Consultants report that nearly all ... responding to requests for proposals. The Aug. ...
(Date:8/1/2014)... Santa Clara, CA (PRWEB) August 01, 2014 ... the availability of EspressReport ES-AMI on AWS Marketplace. ... cloud, with subscriptions starting at $0.50 per hour ... a feature-rich, powerful yet easy-to-use enterprise BI and ... dashboard publishing, visual analytics and ad hoc reporting. ...
(Date:8/1/2014)... iFitDress.com, a professional company of women’s ... of 2014 silver bridesmaid dresses recently. All ... the latest fashion trends. What’s more, they are now ... off. , iFitDress.com is one of the leading ... only silver bridesmaid gowns, but also many other kinds ...
(Date:7/31/2014)... have asthma, you may have an asthma action plan with ... to changes and understand when symptoms are getting worse and ... doing well, yellow means your asthma has worsened and action ... guidelines are now available to help your allergist steer you ... from the red zone. , "Management of acute loss of ...
(Date:7/31/2014)... Leelanau Peninsula’s newest winery, Aurora Cellars ... 7788 East Horn Road in Lake Leelanau. Joining the Northern ... Cellars is the 25th winery along the trail. The winery ... tour events, making its trail event debut during the Harvest ... Owners David and Faye Mathia opened the boutique winery in ...
Breaking Medicine News(10 mins):Health News:Atlantic Information Services Webinar to Offer Health Plan, Employer Strategies for Implementing Narrow Pharma Networks 2Health News:Quadbase Systems Inc. Announces The Availability Of It’s Flagship Enterprise Reporting, Dashboard and BI Analytics Tool on Amazon’s AWS Marketplace 2Health News:iFitDress.com: Beautiful Silver Bridesmaid Dresses at Promotional Prices 2Health News:Aurora Cellars Joins the Leelanau Peninsula Wine Trail 2
... A consortium of federal agencies and nongovernmental organizations has ... and data-collection methods for use in asthma clinical research. ... Outcomes Workshop, which appears as a supplement to the ... and Clinical Immunology , resulted from a meeting organized ...
... FRIDAY, March 2 (HealthDay News) -- Women become less likely ... first year of college, new research finds. Declining condom ... had worse grades and who came from poorer backgrounds. ... unplanned pregnancies and sexually transmitted diseases, yet there has been ...
... people who consume drugs containing cannabinoid compounds found in ... Marsicano (Inserm Research Unit 862) in collaboration with a ... mechanism by which these substances affect working memory. These ... adverse effect of cannabinoids on working memory is exerted ...
... in childhood have a higher risk of infertility in ... Balcerek and her co-authors in a study published in ... 109[7] 126-31). , In a nationwide German survey on ... the authors collected data from former pediatric oncology patients. ...
... By Steven Reinberg HealthDay Reporter , THURSDAY, March ... to screen for cervical cancer are more likely to survive ... Swedish study suggests. Compared to women whose cervical cancer ... Pap smear increased their cure rate from 66 percent to ...
... news for the 27,000 plus people around the world who ... living kidney donors for 10 years found that they were ... general population. Led by Dr. Amit Garg, ... London Health Sciences Centre, the results provide important safety reassurances ...
Cached Medicine News:Health News:Standardized outcome measures proposed for asthma clinical research 2Health News:College Women's Condom Use Falls During Freshman Year 2Health News:How does cannabis affect working memory? 2Health News:How does cannabis affect working memory? 3Health News:Regular Pap Smear Boosts Cervical Cancer Survival: Study 2Health News:Regular Pap Smear Boosts Cervical Cancer Survival: Study 3Health News:First study of its kind finds no increased risk of heart disease for kidney donors 2
(Date:7/31/2014)... SAN DIEGO , July 31, 2014  Sorrento Therapeutics, ... death of Mr. Amar Singh , Chief Business Officer ... of apparent natural causes on July 30. "Sorrento ... dear friend and colleague. Our immediate thoughts go to Amar,s ... President and Chief Executive Officer. Mr. Singh ...
(Date:7/31/2014)... Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ... Insulin Pump, today reported its financial results for the quarter ... second quarter of 2014 to the same period of 2013: ... $5.5 million , t:slim Pump shipments grew 64 percent ... six months ended June 30, 2014 to the same period ...
(Date:7/31/2014)... 31, 2014 Nektar Therapeutics (Nasdaq: NKTR ... ended June 30, 2014. Cash and investments ... as compared to $309.1 million at March 31, 2014."The second ... as we look forward to significant milestones for a number ... and Chief Executive Officer of Nektar. "The first of these ...
Breaking Medicine Technology:Sorrento Announces the Unexpected Death of its Chief Business Officer 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14
... , THOUSAND OAKS, Calif., Dec. 3 Each year, hundreds ... Europe participate in the Amgen Scholars Program to gain hands-on ... universities. Now, the Amgen Scholars - past, present and ... Scholars Community at www.amgenscholars.com . , "The new ...
... MARQUETTE, Mich., Dec. 3 Pioneer Surgical Technology, Inc., ... awards in the Cervical Spine Care category at the ... Francisco, California in conjunction with the North American Spine ... receiving awards were the NuNec® Cervical Total Disc replacement ...
Cached Medicine Technology:New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists 2New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists 3Pioneer(R) Surgical Technology, Inc. Receives Prestigious Spine Technology Awards 2
The CGPL capsulotomy contact glass was designed by Riquin, Fankhauser et al. for the dissection of opacified posterior lens capsules and membranes in the pupillary and retropupillary space with the Y...
The CGAL gonioscopic contact glass was designed by Roussel and Fankhauser for,laser treatments of the chamber angle. It reduces the laser spot by a factor of 1.5 as compared to a Goldmann Glass....
The CGRL is a Wide Angle Contact Glass designed for laser photocoagulation and diagnosis of the retina....
The classic Goldmann Glass. Designed to work with argon/YAG Lasers....
Medicine Products: